ŽUREK, Jiří, Ludmila BARTLOVÁ, Lukáš MAREK a Michal FEDORA. Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children. Česká a slovenská neurologie a neurochirurgie. Praha: ČLS JEP, 2010, roč. 73/106, č. 1, s. 37-44. ISSN 1210-7859.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children
Název česky Sérový protein S100B jako molekulární marker závažnosti poranění mozku u dětí
Název anglicky Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children
Autoři ŽUREK, Jiří (203 Česká republika, garant, domácí), Ludmila BARTLOVÁ (203 Česká republika), Lukáš MAREK (203 Česká republika, domácí) a Michal FEDORA (203 Česká republika, domácí).
Vydání Česká a slovenská neurologie a neurochirurgie, Praha, ČLS JEP, 2010, 1210-7859.
Další údaje
Originální jazyk čeština
Typ výsledku Článek v odborném periodiku
Obor 30000 3. Medical and Health Sciences
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 0.393
Kód RIV RIV/00216224:14110/10:00051304
Organizační jednotka Lékařská fakulta
UT WoS 000275593800005
Klíčová slova česky protein S100; vážný úraz hlavy; výsledek; děti
Klíčová slova anglicky S100protein; severe head injury; outcome; children
Příznaky Mezinárodní význam
Změnil Změnil: Mgr. Michal Petr, učo 65024. Změněno: 12. 4. 2012 12:22.
Anotace
S100B is a protein biomarker that reflects CNS injury. The aims of the current study were to investigate correlations between the initial level of serum S100B protein and mortality and computerized tomography (CT) findings, as well as to establish whether there is an association between S100B and Glasgow outcome scale (GOS) after six months. This prospective study enrolled 43 patients with traumatic brain injury (TBI), verified by computerized tomography and categorized by Marshall classification. Venous blood samples were taken on admission and every 24 h for a maximum of six consecutive days. The outcome was evaluated six months after TBI using the Glasgow outcome scale (GOS) in all patients. GOS was taken as principal end point for all predictive analyses. We demonstrated statistically significant relationships between groups of patients and increased incidence of some types of injury – intracranial bleeding, subdural haematoma, skull fracture, and oedema. The ratio of S100B in 2nd day/initial S100B value significantly differentiated between the groups of patients compared. Levels of S100B were elevated in patients with some specific types of injury, namely intracranial bleeding, subdural haematoma and oedema. The level of S100B was confirmed as a clinically valuable indicator of severity of injury and is proposed as an effective predictor of risk outcome (GOS = 1).
Anotace anglicky
S100B is a protein biomarker that reflects CNS injury. The aims of the current study were to investigate correlations between the initial level of serum S100B protein and mortality and computerized tomography (CT) findings, as well as to establish whether there is an association between S100B and Glasgow outcome scale (GOS) after six months. This prospective study enrolled 43 patients with traumatic brain injury (TBI), verified by computerized tomography and categorized by Marshall classification. Venous blood samples were taken on admission and every 24 h for a maximum of six consecutive days. The outcome was evaluated six months after TBI using the Glasgow outcome scale (GOS) in all patients. GOS was taken as principal end point for all predictive analyses. We demonstrated statistically significant relationships between groups of patients and increased incidence of some types of injury – intracranial bleeding, subdural haematoma, skull fracture, and oedema. The ratio of S100B in 2nd day/initial S100B value significantly differentiated between the groups of patients compared. Levels of S100B were elevated in patients with some specific types of injury, namely intracranial bleeding, subdural haematoma and oedema. The level of S100B was confirmed as a clinically valuable indicator of severity of injury and is proposed as an effective predictor of risk outcome (GOS = 1).
VytisknoutZobrazeno: 18. 7. 2024 00:17